Actively Recruiting
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
Led by Hongmeng Yu · Updated on 2024-02-13
25
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn about the induction chemotherapy efficacy in olfactory neuroblastoma. The main question it aims to answer is: wether olfactory neuroblastoma patients with different pathology subtypes apply to different induction chemotherapy schemes. Participants will be treated with different chemotherapy schemes, to evaluate the tumor remission rate and long term survival.
CONDITIONS
Official Title
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pathologically confirmed olfactory neuroblastoma
- Age 18 years or older
- Dulguerov stage T2 to T4
- Signed informed consent forms
- No distant metastasis
You will not qualify if you...
- Uncontrolled concurrent diseases interfering with treatment
- Conditions that may affect compliance or safety during the study
- Severe neurological or mental illnesses, including dementia and seizures
- Uncontrolled active infections
- Pregnant or lactating women
- Persons without personal freedom or independent civil conduct capacity
- Other situations making participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Eye & ENT Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 200031
Actively Recruiting
Research Team
X
Xiaole Song, MD
CONTACT
J
Jingyi Yang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here